Imaging Core

成像核心

• 批准号: 7670958
• 负责人: Mark A. Mintun
• 金额: $ 72.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7670958
• 关键词: Alzheimer' s Disease; Amyloid; Amyloid Proteins; Amyloid beta-Protein; Amyloid deposition; Anatomy; Archives; Binding; Binding Sites; Biochemical; Biological; Biological Markers; Brain; Brain Injuries; Brain imaging; Cells; Clinical; Collection; Data; Data Set; Databases; Decision Making; Dementia; Deposition; Disease; Evaluation; Functional disorder; Generations; Goals; Hand; Head; Image; Imaging Techniques; Individual; Informatics; Intervention; Late Onset Alzheimer Disease; Magnetic Resonance Imaging; Measures; Metabolic; Metabolism; Morphologic artifacts; Neuronal Dysfunction; Neurons; Noise; Participant; Positron-Emission Tomography; Procedures; Process; Protocols documentation; Psychometrics; Qualifying; Quality Control; Quarantine; Recruitment Activity; Relative (related person); Research Personnel; Resolution; Role; Scanning; Senile Plaques; Series; Signal Transduction; Site; Staging; Standardization; Standards of Weights and Measures; Testing; Time; Work; abeta accumulation; brain tissue; brain volume; density; design; glucose metabolism; gray matter; image processing; insight; interest; neuroimaging; pre-clinical; relating to nervous system

We hypothesize that Alzheimer's disease (AD) has a preclinical stage in which elevated levels of brain amyloid protein and accumulation of beta-amyloid deposits foreshadow the gradual onset of neuronal dysfunction, cell loss and dementia. While the exact role of amyloid in the initiation of brain damage is still unclear, clarifying the exact timing of amyloid deposition that precede AD would be extremely helpful in understanding the biological origins of AD and in designing appropriate interventions. Brain imaging provides a window into many of the hypothesized biochemical, functional and anatomic changes in AD. With Positron Emission Tomography (PET) using [11C]PIB it is possible to estimate the density of beta-amyloid plaques by imaging the PIB binding sites. With PET using [18F]FDG it is possible to estimate neuronal function from measures of metabolic activity. Finally, with magnetic resonance imaging (MRI) volume loss over time can be quantified in regional and global brain measures. It is our premise that by examining the temporal and spatial interrelationships between these three measures important insights will be gained in the pathophysiology of AD. The value of these imaging biomarkers are further enhanced by combining the data with CSF biomarkers and clinical and psychometric data. Towards these goals, the Imaging Core will provide two key support activities to the DIAN effort: Aim 1: Oversee the collection of all image data. This data includes MR scans for morphometrics, PET FDG scans for metabolism and PET PIB scans for imaging beta-amyloid plaques. Aim 2: Perform image processing and analysis to extract biologically relevant measures from the image data set. These measures include whole brain volume and cortical and subcortical regional measures of gray matter volume, relative glucose metabolism and PIB-derived estimates of beta-amyloid plaque deposition.

我们假设阿尔茨海默病（AD）有一个临床前阶段，在这个阶段，大脑中葡萄糖水平升高